Therefore, in terms of tumor therapy, PD-1 blockade might be a double edged sword, on one hand enhancing Tc17 differentiation that might limit tumor rejection, on the other hand promoting switch of established Tc17 cells into Tc1 cells with longevity that drive tumor rejection. The gene discussed is PDCD1; the disease is neoplasm.